Loading…
Employees: 1,388
Size Ind-Swift Laboratories (INDSWFTLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $321M, the 1029th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹348.20 on 6 Nov 2026.
Performance Over six months the shares gained 149.2%, against -25.9% for the median peer and 0.0% for the India market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 66.4% over the last twelve months (peer median -4.4%); the operating margin is 9.4% (peer median 4.9%).
Valuation It trades at 3.5× enterprise value to sales against a peer median of 3.1× (9th most expensive of 20).
Capital Return on invested capital runs 7.6 points below its cost of capital (12.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹7.53B | ₹6.28B | ₹5.64B | ₹17.1B | ₹12.1B |
| Revenue growth | — | +11% | -67% | +42% | — |
| Gross profit | ₹2.57B | ₹1.12B | ₹837M | ₹4.06B | ₹2.57B |
| EBITDA | ₹1.03B | ₹284M | -₹155M | ₹3.07B | ₹2.31B |
| Net income | ₹836M | ₹431M | ₹2.50B | ₹5.39B | ₹476M |
| Free cash flow | n/a | -₹1.06B | -₹965M | -₹5.07B | ₹573M |
| Capital expenditure | n/a | ₹877M | ₹644M | ₹730M | ₹128M |
| Total debt | ₹214M | ₹179M | ₹330M | ₹2.06B | ₹8.53B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INDSWFTLAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.0% | -9.9% | 10th lowest of 20 |
| 6-month return | +149.2% | -25.9% | highest of 20 |
| Distance from 52-week high | -18.4% | -45.8% | 3rd highest of 20 |
| Revenue growth (TTM) | +66.4% | -4.4% | highest of 19 |
| Operating margin | 9.4% | 4.9% | 3rd highest of 20 |
| EV / Sales | 3.5× | 3.1× | 9th most expensive of 20 |
| ROIC minus cost of capital | -7.6 pp | -5.0 pp | 7th lowest of 19 |
| EV / EBITDA | 26.0× | 8.0× | most expensive of 7 |
| Net debt / EBITDA | -3.5× | 2.5× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | 3.5× | n/a | n/a |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | 1,229.5× | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | 4.8× | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | 1.2× | 31.5% | +7.4% |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | 2.5× | 2.7% | +2.3% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | 2.5× | 5.7% | -0.3% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 3.1× | -16.7% | +5.4% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 1.7× | 5.5% | +62.1% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | 1.8× | -10.4% | +10.3% |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | 66.5× | n/a | n/a |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | 7.9× | 58.0% | -12.8% |
| Zhejiang Zhenyuan Share 000705.SZ | China | $312M | -25% | -33% | -5% | 1.1× | n/a | n/a |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 1.0× | -0.1% | -13.7% |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | 5.9× | 28.5% | -6.4% |
| Shanxi C&Y Pharmaceutical 300254.SZ | China | $308M | -44% | -6% | 9% | 3.3× | 10.1% | +0.6% |